Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion type Assertion NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_head.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion description "[Although the anti-EGF receptor (EGFR) monoclonal antibody cetuximab is an effective strategy in colorectal cancer therapy, its clinical use is limited by intrinsic or acquired resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_provenance.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion evidence source_evidence_literature NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_provenance.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion SIO_000772 23166225 NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_provenance.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion wasDerivedFrom befree-20140225 NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_provenance.
- NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_assertion wasGeneratedBy ECO_0000203 NP248024.RAtyk6P3Im3YEyhQwbDwRWluTM6hGH4zBhlGPKsk0WtGs130_provenance.